CLD-501

CLD-501 is an investigational therapeutic candidate being developed by Calidi Biotherapeutics, utilizing a combination of oncolytic virus therapy and gene therapy. It is currently positioned in the company's pipeline for the treatment of multiple myeloma and various autoimmune diseases. While specific details regarding its viral backbone and genetic payload are proprietary and undisclosed, CLD-501 is expected to leverage Calidi’s core technology of using donor-derived cells to protect and deliver oncolytic viruses, potentially overcoming the limitations of systemic administration such as neutralization by the host immune system. This approach aims to enhance the precision and efficacy of viral delivery to target tissues while minimizing off-target effects.